TELA Bio amends 8-K to detail former CEO Koblish separation benefits
Reuters2026/08/13 20:10- TELA Bio amended a prior 8-K to add details of a separation agreement with former CEO Antony Koblish, effective Aug. 7.
- Agreement provides 12 months of base-salary severance, paid in installments, covering the period following his Aug. 3 exit.
- All equity awards immediately accelerated to full vesting; option exercise window extended to the earlier of Dec. 31, 2027 or expiry.
- COBRA coverage available through Aug. 31; company to pay premiums for 12 months if elected by Sept. 1.
- Performance stock units remain eligible to vest through Dec. 31, 2026, with target vesting on a change in control by then.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
